NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Supernus Pharmaceuticals, Inc. SUPN
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$719.0M
▲ 8.6% vs FY2024
EPS · FY25
$-0.68
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-3.7%
Net margin · FY25
-5.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 719.0M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 5 cents on every revenue dollar this year.
Per share
USD -0.68
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-3.7%
Return on equity, FY2025
ROE
Operating margin-8.7%
Net margin-5.4%
Return on assets-2.7%
Each USD of equity lost 4 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+6.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.5%
+6.7%
+17.2%
+80.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+8.7%
Change, 10 years+17.2%
The share count grew 9% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.5B
total assets, end of FY2025
Total assetsUSD 1.5B
EquityUSD 1.1B
CashUSD 128.4M
Current ratio1.90×
Equity funds 73% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.7
0.7
0.6
0.7
0.6
0.5
0.4
0.4
0.3
0.2
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.1
0.1
−0.0
0.0
0.1
0.2
0.1
0.1
0.1
0.1
0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
0.0
0.2
0.1
0.1
0.1
0.2
0.2
0.2
0.1
0.1
0.0
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.0
0.1
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
−0.0
−0.1
−0.0
0.1
−0.0
EPS, diluted $
−0.68
1.32
0.02
1.04
0.98
2.36
2.10
2.05
1.08
1.76
0.28
−0.26
−2.90
−2.72
31.39
−26.38
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−3.7
7.5
0.1
7.1
6.8
18.9
21.6
30.8
24.9
65.2
21.7
−29.5
−202.7
−138.1
·
·
Shares out B
0.06
0.06
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 46
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed